Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. The firm's lead product includes FB-401, which is a live biotherapeutic for the treatment of inflammatory skin disease, including pediatric and adult patients with atopic dermatitis. The company was founded by Paul A. Wagner in 2017 and is headquartered in Dallas, TX.
相关临床试验
6
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2017
已完成
1
16.7%
招募中
4
66.7%
终止
1
16.7%
暂无批准数据
- FB102 achieved a 29.6% mean improvement from baseline in Facial Vitiligo Area Scoring Index (FVASI) at week 24, reaching statistical significance versus placebo. - Among patients with greater disease involvement (FVASI ≥0.75), FB102 produced a 43.2% mean FVASI improvement, with 58.8% achieving FVASI50 and 23.5% achieving FVASI75. - Improvements were observed as early as day 64 and continued to increase after the 12-week treatment period ended, with 84% of FB102-treated patients improving through week 24. - FB102 maintained a favorable safety profile with adverse events generally mild to moderate and comparable to placebo, reinforcing its potential as an immune-modulating therapy targeting CD122.
- Over 18 companies are actively developing 20+ pipeline therapies for vitiligo treatment, with JAK inhibitors leading the charge in late-stage clinical trials. - AbbVie's Upadacitinib and Pfizer's Ritlecitinib have both advanced to Phase 3 trials, demonstrating promising repigmentation results in vitiligo patients. - Novel approaches include Clinuvel's Afamelanotide in Phase 3 trials and Amgen's AMG 714 anti-IL-15 monoclonal antibody in Phase 2 development. - The pipeline reflects a paradigm shift towards targeted therapies and personalized medicine approaches, offering new hope for patients with this challenging autoimmune condition.
